The principal findings of this study are 1) glioma-associated CCR2+/CX3CR1+ myeloid cells are sourced from the bone marrow, 2) CCR2+/CX3CR1+ cells suppress both CD4+ and CD8+ T cells 3) CCR2+/CX3CR1+ cells migrate to recombinant and glioma-produced CCL2 and CCL7 in a redundant manner 4) and dual targeting CCL2 and CCL7 reduces these cells in the glioma. This evidence concerns the gene CCR2 and central nervous system cancer.